UNLABELLED: Overweight has been reported as a cause for the nonvisualization of sentinel nodes (SNs) on preoperative planar lymphoscintigraphy in patients with breast cancer. The purpose of this study was to assess whether SPECT/CT may improve SN identification in overweight patients. METHODS: Lymphoscintigraphy was performed in 220 consecutive patients with breast cancer. Body mass index (BMI) was calculated for each. A total of 122 patients were overweight or obese (BMI, > or = 25). Planar images and SPECT/CT images were interpreted separately, and SN identification on each of the modalities was related to BMI and to findings at surgery. RESULTS: Planar imaging identified SNs in 171 patients (78%) with a BMI (mean +/- SD) of 25.2 +/- 4 kg/m2 and failed to do so in 49 patients (22%) with a BMI of 28 +/- 8 kg/m2. In 29 of the latter patients (59%), SNs were identified on SPECT/CT. SPECT/CT detected "hot" nodes in 200 patients (91%) and failed to do so in 20 patients with a BMI of 29.2 +/- 6.6 kg/m2. For the 122 overweight or obese patients, planar assessment failed to identify SNs in 34 patients (28%) and SPECT/CT failed to do so in 13 patients (11%) (P < 0.001). For 116 patients, surgery took place in our hospital (Tel-Aviv Sourasky Medical Center). An intraoperative blue dye technique failed to detect SNs in 48 patients (41%) with a BMI of 28.2 +/- 7 kg/m2. SPECT/CT localized hot nodes in 36 (75%) of the latter patients, and planar imaging did so in 22 (46%) of those patients. Of 19 patients for whom scintigraphy failed, 6 (32%) had nodal metastatic involvement. CONCLUSION: The addition of SPECT/CT to lymphoscintigraphy improved SN identification in overweight patients with breast cancer. Moreover, SPECT/CT accurately identified SNs in 75% of patients for whom the identification of SNs by the intraoperative blue dye technique failed.
UNLABELLED: Overweight has been reported as a cause for the nonvisualization of sentinel nodes (SNs) on preoperative planar lymphoscintigraphy in patients with breast cancer. The purpose of this study was to assess whether SPECT/CT may improve SN identification in overweight patients. METHODS: Lymphoscintigraphy was performed in 220 consecutive patients with breast cancer. Body mass index (BMI) was calculated for each. A total of 122 patients were overweight or obese (BMI, > or = 25). Planar images and SPECT/CT images were interpreted separately, and SN identification on each of the modalities was related to BMI and to findings at surgery. RESULTS: Planar imaging identified SNs in 171 patients (78%) with a BMI (mean +/- SD) of 25.2 +/- 4 kg/m2 and failed to do so in 49 patients (22%) with a BMI of 28 +/- 8 kg/m2. In 29 of the latter patients (59%), SNs were identified on SPECT/CT. SPECT/CT detected "hot" nodes in 200 patients (91%) and failed to do so in 20 patients with a BMI of 29.2 +/- 6.6 kg/m2. For the 122 overweight or obesepatients, planar assessment failed to identify SNs in 34 patients (28%) and SPECT/CT failed to do so in 13 patients (11%) (P < 0.001). For 116 patients, surgery took place in our hospital (Tel-Aviv Sourasky Medical Center). An intraoperative blue dye technique failed to detect SNs in 48 patients (41%) with a BMI of 28.2 +/- 7 kg/m2. SPECT/CT localized hot nodes in 36 (75%) of the latter patients, and planar imaging did so in 22 (46%) of those patients. Of 19 patients for whom scintigraphy failed, 6 (32%) had nodal metastatic involvement. CONCLUSION: The addition of SPECT/CT to lymphoscintigraphy improved SN identification in overweight patients with breast cancer. Moreover, SPECT/CT accurately identified SNs in 75% of patients for whom the identification of SNs by the intraoperative blue dye technique failed.
Authors: Iris M C van der Ploeg; Omgo E Nieweg; Bin B R Kroon; Emiel J T Rutgers; Marie-Jeanne T F D Baas-Vrancken Peeters; Wouter V Vogel; Cornelis A Hoefnagel; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2009-01-13 Impact factor: 9.236
Authors: Giuliano Mariani; Laura Bruselli; Torsten Kuwert; Edmund E Kim; Albert Flotats; Ora Israel; Maurizio Dondi; Naoyuki Watanabe Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-25 Impact factor: 9.236
Authors: Sergi Vidal-Sicart; Fijs W B van Leeuwen; Nynke S van den Berg; Renato A Valdés Olmos Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-22 Impact factor: 9.236
Authors: Ingo Stoffels; Ken Herrmann; Jan Rekowski; Philipp Jansen; Dirk Schadendorf; Andreas Stang; Joachim Klode Journal: Trials Date: 2019-02-04 Impact factor: 2.279
Authors: Thomas Wendler; Ken Herrmann; Andreas Schnelzer; Tobias Lasser; Joerg Traub; Olivier Kutter; Alexandra Ehlerding; Klemens Scheidhauer; Tibor Schuster; Marion Kiechle; Markus Schwaiger; Nassir Navab; Sibylle I Ziegler; Andreas K Buck Journal: Eur J Nucl Med Mol Imaging Date: 2010-03-31 Impact factor: 9.236
Authors: J Serrano-Vicente; J I Rayo-Madrid; M L Domínguez-Grande; J R Infante-Torre; L García-Bernardo; M Moreno-Caballero; F Medina-Romero; C Durán-Barquero Journal: Clin Transl Oncol Date: 2015-08-18 Impact factor: 3.405